Skip to main content
PRTA
NASDAQ Life Sciences

Prothena Posts Q2 Results, Highlights $3B in Potential Milestones from Partnered Pipeline

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$8.58
Mkt Cap
$449.191M
52W Low
$7.28
52W High
$11.8
52W Position info
18% above low
Off High info
27% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

PRTA sits 18% above its 52-week low of $7.28.

Summary

Prothena reported Q2 2026 financials and updated on its partnered pipeline. The company highlighted that its partnered programs could generate up to $3 billion in future milestone payments plus royalties. Key updates include Roche's publication of Phase 2b PADOVA data in The Lancet, supporting prasinezumab's disease-modifying potential in Parkinson's, and the advancement of coramitug and moponetug into Phase 3 and Phase 2 trials, respectively. Additionally, Prothena completed a Phase 1 study for PRX019 and expects a $55 million milestone decision from Bristol Myers Squibb by year-end 2026. The financial results themselves are routine for a clinical-stage biotech, but the pipeline progress and milestone potential provide a meaningful update on the company's value drivers. With a market cap around $450 million, the $3 billion milestone figure underscores the significant upside tied to partner execution. The next major catalysts are the BMS decision on PRX019 by YE 2026 and Phase 2 TargetTau-1 completion in 1H 2027.

At the time of this announcement, PRTA was trading at $8.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $449.2M. The 52-week trading range was $7.28 to $11.80. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

PRTA - Latest Insights

PRTA
Nov 05, 2026, 5:55 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.89
Real-time Price: $7.89 info
Change: $0 (0%) info
Market Cap: $405.049M info
PRTA
Nov 05, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.89
Real-time Price: $7.89 info
Change: $0 (0%) info
Market Cap: $405.049M info
PRTA
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.88
Real-time Price: $7.89 info
Change: -$0.990 (-11%) info
Market Cap: $405.049M info
PRTA
Aug 06, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.58
Real-time Price: $7.89 info
Change: -$0.690 (-8%) info
Market Cap: $405.049M info
PRTA
Jun 09, 2026, 8:00 AM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $8.71
Real-time Price: $7.89 info
Change: -$0.820 (-9%) info
Market Cap: $405.049M info